CowellA, ShenoiSV, KyriakidesTC, et al.: Trends in hospital deaths among human immunodeficiency virus-infected patients during the antiretroviral therapy Era, 1995 to 2011. J Hosp Med, 2015; 10:608–614.
2.
BhaskaranK, HamoudaO, SannesM, et al.: Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA, 2008; 300:51–59.
3.
DjaweK, BuchaczK, HsuL, et al.: Mortality risk after AIDS-defining opportunistic illness among HIV-infected persons–San Francisco, 1981–2012. J Infect Dis, 2015:212:1366–1375.
4.
SchwarczL, ChenMJ, VittinghoffE, et al.: Declining incidence of AIDS-defining opportunistic illnesses: Results from 16 years of population-based AIDS surveillance. AIDS, 2013; 27:597–605.
5.
LimaVD, LourencoL, YipB, et al.: AIDS incidence and AIDS-related mortality in British Columbia, Canada, between 1981 and 2013: A retrospective study. Lancet, 2015; 2:e92–e97.
6.
FauciAS, MarstonHD: Ending the HIV-AIDS pandemic- follow the science. NEJM, 2015; 373:2197–2199.
7.
AnQ, SongR, HernandezA, HallHI: Trends and differences among three new indicators of HIV infection progression. Public Health Rep, 2015; 130:468–474.
8.
LemlyDC, ShepherdBE, HulganT, et al.: Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. J Infect Dis, 2009; 199:991–998.
9.
AdihWK, SelikRM, HuX: Trends in diseases reported on US death certificates that mentioned HIV infection, 1996–2006. J Int Assoc Physicians AIDS Care, 2011; 10:5–11.
10.
GrantPM, KomarowL, SanchezA, et al.: Clinical and immunologic predictors of death after an acute opportunistic infection: Results from ACTG A5164. HIV Clin Trials, 2014; 15:133–139.
11.
KimJH, PsevdosG, GonzalezE, et al.: All- cause mortality in hospitalized HIV-infected patients at an acute tertiary care hospital with a comprehensive outpatient HIV care program in New York City in the era of highly active antiretroviral therapy (HAART). Infection, 2013; 41:545–551.
12.
MasurH, ReadSW: Opportunistic infections and mortality: Still room for improvement. J Infect Dis, 2015; 212:1348–1350.
13.
MillerRF, HuangL, WalzerPD: Pneumocystis pneumonia associated with human immunodeficiency virus. Clin Chest Med, 2013; 34:229–241.
14.
Lopez-SanchezC, FalcoV, BurgosJ, et al.: Epidemiology and long-term survival in HIV-infected patients with pneumocystis jirovecii pneumonia in the HAART Era. Medicine, 2015; 94:1–8.
15.
ScherzerR, HeymsfieldSB, LeeD, et al.: Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. AIDS, 2011; 25:1405–1414.
16.
BrizendineKD, BaddleyJW, PappasPG: Predictors of mortality and differences in clinical features among patients with cryptococcosis according to immune status. PLoS One, 2013; 8:e60431.
17.
BrattonEW, HusseiniNE, ChastainCA, et al.: Comparison and temporal trends of three groups with cryptococcosis: HIV- infected, solid organ transplant, and HIV-negative/non-transplant. PLoS One, 2012; 7:e43582.
18.
ShunS, ModyCH: Cryptococcus. Proc Am Thorac Soc, 2010; 7:186–196.
19.
LanoyE, GuiguetM, BenataM, et al.: Survival after neuro AIDS. Neurology, 2011; 76:644–651.
20.
WrightE: Neurocognitive impairment and neuroCART. Curr Opin HIV AIDS, 2011; 6:303–308.
21.
O'ConnorRM, ShaffieR, KangG, WardHD: Cryptosporidiosis in patients with HIV/AIDS. AIDS, 2011; 25:549–560.
22.
JabsDA, MartinBK, FormanMS: Mortality associated with resistany cytomegalovirus among patients with cytomegalovirus retinitis and AODS. Opthalmology, 2010; 117:128.
23.
KemperJH, JabsDA, WilsonLA, et al.Mortality risk for patients with cytomegalovirus retinitis and acquired immunodeficiency syndrome. Clin Infect Dis, 2003; 37:1365–1373.
24.
HoffmanC, ErnstM, WolfE, et al.: Evolving characteristics of toxoplasmosis in patients infected with human immunodeficiency virus-1: Clinical course and Toxoplasma gondii-specific immune responses. Clin Microbiol Infect, 2007; 13:510–515.
25.
LimaMA, Bernal-CanoF, CliffordDB, et al.: Clinical outcome of long-term survivors of progressive multifocal leukoencephalopathy. J Neurol Neurosurg Psychiatry, 2010; 81:1288–1291.
26.
DelbueS, EliaF, CarloniC, et al.: JC virus load in cerebrospinal fluid and transcriptional control region rearrangements may predict the clinical course of progressive multifocal leukoencephalopathy. J Cell Physiol, 2012; 227:3511–3517.
27.
CasadoJL, CorralI, GarciaJ, et al.: Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV/AIDS patients in the current era. Eur J Clin Microbiol Infect Dis, 2014; 33:179–187.
